Download/Order Form
* = Required Field |
|
|
|
Part One |
This newsletter presents the case of a 52-year-old restaurant manager, who, after initial treatment of stage III ovarian cancer with combination chemotherapy, experiences disease recurrence within 5 months. This case examines the appropriate choice for initial treatment, for recurrent disease, as well as the appropriate dose and schedule for second-line therapy. The discussion of this case emphasizes practical strategies for determining effective dosing sequencing, in light of recent clinical trial data.
|
|
Part Two |
This newsletter, the second in a series of eight on gynecologic cancers, presents the case of a 67-year-old patient with fallopian tube carcinoma, who experienced a recurrence after 4 years of remission. The discussion of this case, which highlights the similarity of this patient’s disease management to that of someone with ovarian cancer, focuses on the most appropriate chemotherapeutic choices for second-line treatment.
|
|
Part Three |
This newsletter presents the case of a 49-year-old woman with metastatic small-cell cervical cancer. This unusual case has important implications that are widely applicable to patients with all varieties of cancer, as it illustrates the importance of weighing quality of life against the toxicities of therapy in choosing and sequencing appropriate chemotherapy regimens.
|
| |
Part Four |
This newsletter presents the case of a 74-year-old patient with UPSC of the endometrium whose disease recurs with abdominal metastasis. This case identifies the similarities between UPSC and ovarian cancer, explores reasonable chemotherapy choices and dosing schedules, and discusses treatment response measures.
|
| |
Part Five |
This Tx Reporter presents the case of a 45-year-old woman who develops recurrent ovarian cancer. The case explores the significance and utility of CA-125 levels as a marker of disease and treatment response. It also elaborates on the pros and cons of various treatment options for second-line therapy and considers the issue of timing and sequencing of these therapies.
|
| |
Part Six |
This newsletter presents the case of a 54-year-old woman with no prior smoking history who is diagnosed with stage IV non–small-cell lung cancer (NSCLC), specifically an adenocarcinoma. The patient’s presentation is not uncommon for NSCLC in 2003. The absolute number of new cases in women continues to rise yearly in the United States, and while cigarette smoking continues to be the most identifiable risk factor for lung cancer, there appears to be a higher percentage of nonsmokers developing the disease. Adenocarcinoma is now the most common subtype and is typical for a patient with no smoking history.
|
| |
Part Seven |
This Tx Reporter presents the case of a 71-year-old man with stage IV adenocarcinoma with a solitary distant adrenal metastasis. This case discussion highlights the need for disease management based on the patient’s presentation, as well as the clinical decisions unique to a solitary adrenal mass.
|
|
Part Eight |
This Tx Reporter presents the case of a 65-year-old woman who has limited-stage SCLC. After achieving a complete response to first-line therapy, her disease recurs with multiple metastases to the bone. This case discusses staging and first-line therapy for limited-stage SCLC. It also describes treatment options for recurrence, including the option of a drug holiday during a time of stable disease.
|
| |
Part Nine |
This Tx Reporter uses the case of a 42-year-old cervical cancer patient to illustrate the possible roles for chemotherapy agents both as radiosensitizers in chemoradiation for locally advanced disease and as treatment for advancedstage or recurrent disease. Dr. Alvarez discusses the current standard of care using platinum-based regimens and future directions with newer agents, such as topotecan.
|
| |
Part Ten |
This Tx Reporter focuses on a 54-year-old executive with a 1.9 cm solitary pulmonary nodule, first detected with spiral CT scan. This type of CT scan detects more small thoracic nodules than standard CT, because the singlebreath hold eliminates the patient motion artifact. The treatment choices featured in this case highlight the role of surgical resection, platinum-based and novel chemotherapies, and prophylactic cranial irradiation in the treatment of small-cell lung cancer.
|
| |
Part Eleven |
In this case presentation, a 53-year-old florist has an elevated CA-125 level after her ovarian cancer responded to carboplatin/paclitaxel. This newsletter probes questions about monitoring for disease recurrence and deciding the appropriate time to initiate second-line treatment. It also explores the benefits and risks of available therapies and dosing schedules, citing the latest data and providing information about ongoing investigations.
|
| |
Part Twelve |
In Part 12, we explore in more detail the rationale for development of
weekly dosing and the emerging data as they apply to lung and gynecologic cancers. This information is designed to complement what you have already learned in the course of this series about the standard of care and emerging strategies in the treatment of ovarian, endometrial, cervical, and lung cancers.
|
|
Check to save the information
below on your computer |
| *First name |
|
| MI |
|
| *Last name |
|
*Credentials
(eg, MD, DO, etc) |
|
| Specialty |
|
*Office address
Line1 |
|
*Office address
Line2 |
|
| *City |
|
| *State |
|
| *ZIP |
|
*Office Phone
for confirmation only |
|
*Office Fax
for confirmation only |
|
*E-mail
|
|
|
YES, this confirms that you may fax/e-mail me
to confirm my order, (in lieu of my signature) |
|
YES, this confirms that you may fax/e-mail me
regarding future CME activities, (in lieu of my signature) |
How did you find out
about this activity?:
Other? Please specify |
|